Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-01-22 Earnings Release
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for HanAll Biopharma. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the 4th quarter of 2024 compared to previous periods. It explicitly states that these are provisional figures (잠정치) and are subject to change after external audit. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results. Q4 2024
2025-01-22 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from HanAll Biopharma regarding a significant change in sales or profit/loss structure (30% or more). This is a standard periodic financial disclosure required by the Korea Exchange (KRX) for listed companies to announce preliminary financial results before the final audit report is filed. It provides key financial highlights (revenue, operating profit, net income) and explanations for the changes. It fits the definition of an Earnings Release (ER) as it is an initial announcement of financial results. FY 2024
2025-01-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding HanAll Biopharma. This type of filing is specifically used to report changes in shareholding by major shareholders (10% or more) or insiders. In the provided taxonomy, this corresponds to a Major Shareholding Notification (MRQ), as it details the change in ownership percentage and specific transaction history of a major shareholder.
2025-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the National Pension Service's shareholding changes in HanAll Biopharma. This type of filing is specifically designed to report changes in significant share ownership levels (crossing thresholds) by major shareholders, which aligns with the 'Major Shareholding Notification' category.
2024-12-26 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement from HanAll Biopharma regarding the setting of a record date and shareholder register closure period for the purpose of holding the 52nd Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal regulatory notice of the upcoming meeting's administrative requirements. As it is a standard regulatory disclosure regarding corporate governance procedures, it fits best under the RNS category.
2024-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details changes in shareholdings by the National Pension Service (a major shareholder) in HanAll Biopharma. This type of filing is a standard regulatory disclosure for major shareholding changes (often referred to as the '5% rule' or 'major shareholding notification' in Korean capital markets).
2024-11-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.